NYSE Euronext today announced the listing of MEDIAN Technologies, a provider of software and services specialized in clinical and diagnostic applications that use medical imaging in oncology, on NYSE Alternext in Paris.
Founded in 2002, MEDIAN Technologies is a software developer and service provider, specialized in clinical solutions that make use of medical imaging. Its applications help radiologists, oncologists, and more generally all specialists who prescribe radiological exams to read, detect, quantify and track test results. The company has a staff of 40, more than half of whom work in R&D, and has a subsidiary in the USA.
MEDIAN Technologies (ticker code: ALMDT) was listed through admission to trading of 5,588,838 existing shares including 1,239,356 new shares issued in a private offering to qualified investors. The total amount raised was €9.98 million.
The admission and issue price of MEDIAN Technologies shares was set at €8.05. Market capitalization stood at €45 million on the day of listing.
“We are very pleased to welcome MEDIAN Technologies to NYSE Alternext. MEDIAN Technologies is an innovative company that understands the pharmaceutical industry’s need for better diagnostics and tracking of patients with serious illnesses,” said Ronald Kent, Group Executive Vice President and head of international listings at NYSE Euronext. “By making the strategic decision to undertake an IPO, MEDIAN Technologies will increase its visibility and facilitate future growth.”
Fredrik Brag, Chairman and CEO of MEDIAN Technologies, added, “We have developed an innovative solution for oncology imaging analysis. The system is particularly well suited to resolving the issues encountered in clinical trials and has already been adopted by three of the largest pharma companies. The recent round of fundraising and today’s IPO will provide the necessary financing for the commercialization of our solutions and services and I wish to thank the investors who have provided us with their support.”
In six years, 165 companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US have raised €2.4 billion on NYSE Alternext, half of this through secondary issues. Their combined market capitalization totals €5.6 billion.